Evidence map›Paper›PMID 41727163›Full record

ArticlebioRxiv : the preprint server for biology2026

EBV Type 1 versus Type 2: A determinant of NK cell anti-tumor activity in Burkitt lymphoma.

Catherine S Forconi, Lauren Shumate, Zachary Racenet, Viriato M'Bana, Cliff Oduor, Angela Matta, Jeni Melo, Peter O Oluoch, Boaz Odwar, Juliana Otieno and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Catherine S ForconiDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester MA, USA.ORCID 0000-0001-7358-5546
Lauren ShumateDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester MA, USA.
Zachary RacenetDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester MA, USA.
Viriato M'BanaDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester MA, USA.
Cliff OduorDepartment of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, USA.
Angela MattaDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester MA, USA.
Jeni MeloDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester MA, USA.
Peter O OluochDepartment of Microbiology, University of Massachusetts Chan Medical School, Worcester MA, USA.
Boaz OdwarCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Juliana OtienoJaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya.
Terry A VikDepartment of Pediatrics, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Festus N'jugunaDepartment of Child Health and Paediatrics, Moi University, Eldoret, Kenya.
Ann W KinyuaCenter for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Jeffrey A BaileyDepartment of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, USA.
Christian MünzInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Ann M MoormannDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester MA, USA.ORCID 0000-0003-1113-2829

Funding

Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphomaR01CA189806 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MOORMANN, ANN M · 2014 to 2024
$5.7M
NCI NIH HHS R01 CA189806
6 · The paper itself

Abstract

Terminally differentiated CD56

Indexed as

antibody-dependent cell cytotoxicity (ADCC)Burkitt lymphoma (BL)CD56negEpstein-Barr virus (EBV) type 1 and type 2NK cellspediatric cancerrituximab

Identifiers

PMID41727163
PMCPMC12918908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.